BioSpace News Archive

The newest addition to the Illumina oncology portfolio offers researchers the ability to measure Tumor Mutational Burden and Microsatellite Instability, and detect other known and emerging biomarkers

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial results for its fiscal first quarter, ended September 30, 2018.

Scientists Find New Member of Toxic Chemical Family Everywhere They Look

Proceeds to Support Development of Clinical and Preclinical NASH Candidates

Cyrus Biotechnology, Inc. announced today that through a collaboration with OpenEye Scientific Software, Inc., a leader in computational molecular design, capabilities have been developed that allow small molecule ligands to be processed and used with Rosetta and within the Cyrus Bench® platform for computational protein drug design.

COMPANY INCREASES FULL-YEAR 2018 GUIDANCE

Co-Developed Exam Planned to Launch In 10 US Centers in Q1 2019; Projected to be Used in 100 Vascular Surgery Training Programs Throughout US

For the quarter, Welltower generated net income attributable to common stockholders of $0.17 per share and normalized FFO attributable to common stockholders of $1.04 per share.

Third-Quarter 2018 Revenues of $13.3 Billion, Reflecting 2% Operational Growth

Results from Phase 1 trial highlight ZW25’s single agent effect in HER2-driven cancers